{"page_content": "12      KODIAK 2021 ESG REPORT BACK TO CONTENTS >>\nGovernance \nWe believe that establishing sound principles of corporate governance is vital  \nto providing long-term value for our stakeholders, including patients, employees, \nshareholders and the broader communities in which we operate. We recognize \nthat clearly defining expectations and emphasizing personal and corporate \naccountability are critical steps in accomplishing this.\nLEADING WITH PURPOSE AND INTEGRITY\nKodiak\u2019s Board is responsible for serving the best long-term interests of our \nshareholders and overseeing the company\u2019s mission to design and develop \ninnovative new medicines for highly prevalent ophthalmic diseases. The Board has \napproved Corporate Governance Guidelines which outline governance principles  \nand responsibilities of our Board.\nThe Kodiak Board provides oversight on ESG matters, with related duties delegated \nto certain of our Board committees. \nTHE NOMINATING \nAND GOVERNANCE \nCOMMITTEE \ndevelops and updates our \ncorporate governance \nguidelines, which covers \nmatters such as reviewing \nthe roles and composition \nof Board committees. \nThe committee considers \nESG matters and makes \nrecommendations  \nregarding such matters.THE AUDIT COMMITTEE \noversees the Company\u2019s \naccounting and financial \nreporting processes and \nour compliance with \napplicable regulations. \nAn important role of the \ncommittee is evaluating \nthe independence of the \ncompany\u2019s registered \npublic accounting firm.THE COMPENSATION \nCOMMITTEE\nreviews, makes \nrecommendations, and \napproves the compensation \narrangements and benefits  \nof our CEO and other \nexecutive officers. ", "metadata": {"source": "NASDAQ_KOD_2021.pdf", "page": 11, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}